Why Early Detection Is Critical Lung cancer remains the deadliest cancer globally, with nearly 2.5 million new cases diagnosed each year. Significantly, 10–25% of cases now occur in non-smokers, with environmental factors such as air pollution playing a notable role. Due to low screening rates—particularly within underserved populations—most lung cancers are detected at advanced stages. This highlights a major opportunity: Pharma must expand risk education and screening outreach beyond smoking-related history to help identify cases sooner. Precision Medicine and Immunotherapy Are Changing Outcomes Treatment advances in non-small-cell lung cancer (NSCLC) have accelerated, with 11 new FDA approvals in recent years. Targeted therapies and immunotherapies now offer improved survival outcomes, particularly for patients with actionable genomic alterations. These innovations are increasingly being applied to early-stage and maintenance settings, changing the landscape for patient care. The industry’s next step: Empower development teams to enable smarter trial design and accelerate novel therapy launches through collaboration in precision medicine, biomarker research and multi-omics data. Hidden Barriers in the Patient Journey Despite therapeutic innovation, clinical trial participation remains low. Only 2–8% of eligible lung cancer patients enrol, and 25% of trials fail to meet recruitment targets. Key challenges include: -Limited awareness among patients and healthcare professionals -Complex eligibility criteria -Structural obstacles within healthcare systems Pharma can help overcome these barriers by working with patient advocacy groups and leveraging digital tools for education and trial-matching support. Biomarker Testing Should Be Standard Practice Comprehensive biomarker testing guides targeted lung cancer treatment, yet its adoption remains inconsistent. While survival rates have improved by 26% over five years, access to testing and funding gaps persist. Barriers span policy, healthcare systems and provider training. Pharma must support educational efforts and policy advocacy to help ensure biomarker testing becomes a routine and accessible part of lung cancer care. Health Equity in Lung Cancer Research Health disparities continue to affect outcomes. People from ethnic minority backgrounds often experience delayed diagnoses, reduced access to guideline-based care and poorer survival. Promising innovations include: -Real-time data tracking -Artificial intelligence screening tools -Mobile screening units -Patient navigation service Future research is increasingly focused on combination therapies, overcoming treatment resistance and tailoring care for underserved communities. Pharma companies must embed health equity priorities within research design and implementation to extend the reach of innovation. If your brand teams are ready to drive impact, and make insights turn into actionable strategies for your lung cancer portfolio, reach out to our oncology team, HRW OR:BIT, at HRW-ORBIT@hrwhealthcare.com or alternatively fill out the contact form below. Apply Now!